



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Berotrastat (Standard)

<b>Cat. No.:</b>	HY-109127R
<b>CAS No.:</b>	1809010-50-1
<b>Molecular Formula:</b>	C <sub>30</sub> H <sub>26</sub> F <sub>4</sub> N <sub>6</sub> O
<b>Molecular Weight:</b>	562.56
<b>Target:</b>	Ser/Thr Protease
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Berotrastat (Standard) is the analytical standard of Berotrastat. This product is intended for research and analytical applications. Berotrastat (BCX7353) is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotrastat works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Plasma kallikrein <sup>[1]</sup>

### REFERENCES

- [1]. Zuraw B, et al. Oral once-daily berotrastat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. *J Allergy Clin Immunol.* 2020;S0091-6749(20)31484-6.
- [2]. Manning ME, et al. Berotrastat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies. *Allergy Asthma Proc.* 2021;42(4):274-282.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA